Neutrophils in MASLD and MASH (original) (raw)

1. Ching-Yeung Yu B, Kwok D and Wong VW (2019) Magnitude of nonalcoholic fatty liver disease: eastern perspective. J Clin Exp Hepatol 9, 491-496.
   
2. Rinella ME, Lazarus JV and Ratziu V et al (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966-1986.
   
3. Zobair Y, Maria S and Janus PO et al (2019) Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol H 17, 748-755.e743.
   
4. Younossi Z, Anstee QM and Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15, 11-20.
   
5. Teng ML, Ng CH and Huang DQ et al (2023) Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol 29, S32-S42.
   
6. Murag S, Ahmed A and Kim D (2021) Recent epidemiology of nonalcoholic fatty liver disease. Gut Liver 15, 206-216.
   
7. Huang DQ, El-Serag HB and Loomba R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18, 223-238.
   
8. Le MH, Yeo YH and Zou B et al (2022) Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol 28, 841-850.
   
9. Raza S, Rajak S, Upadhyay A, Tewari A and Anthony Sinha R (2021) Current treatment paradigms and emerging therapies for NAFLD/NASH. Front Biosci (Landmark Ed) 26, 206-237.
   
10. Yang Z and Wang L (2023) Current, emerging, and potential therapies for non-alcoholic steatohepatitis. Front Pharmacol 14, 1152042.
    
11. Amulic B, Cazalet C, Hayes GL, Metzler KD and Zychlinsky A (2012) Neutrophil function: from mechanisms to disease. Annu Rev Immunol 30, 459-489.
    
12. Chen S, Guo H, Xie M, Zhou C and Zheng M (2021) Neutrophil: an emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol 97, 107609.
    
13. Kolaczkowska E and Kubes P (2013) Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 13, 159-175.
    
14. Chen GY and Nunez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10, 826-837.
    
15. Wang J (2018) Neutrophils in tissue injury and repair. Cell Tissue Res 371, 531-539.
    
16. Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T and Chatzigeorgiou A (2016) The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord 17, 29-39.
    
17. Hundertmark J, Krenkel O and Tacke F (2018) Adapted Immune responses of myeloid-derived cells in fatty liver disease. Front Immunol 9, 2418.
    
18. Gao B and Tsukamoto H (2016) Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?. Gastroenterology 150, 1704-1709.
    
19. Rensen SS, Bieghs V and Xanthoulea S et al (2012) Neutrophil-derived myeloperoxidase aggravates non-alcoholic steatohepatitis in low-density lipoprotein receptor-deficient mice. PLoS One 7, e52411.
    
20. Ou R, Liu J and Lv M et al (2017) Neutrophil depletion improves diet-induced non-alcoholic fatty liver disease in mice. Endocrine 57, 72-82.
    
21. Friedman SL, Neuschwander-Tetri BA, Rinella M and Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24, 908-922.
    
22. Birkenfeld AL and Shulman GI (2014) Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59, 713-723.
    
23. Musso G, Gambino R and Cassader M (2009) Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res 48, 1-26.
    
24. Menezes AL, Pereira MP and Buzelle SL et al (2013) A low-protein, high-carbohydrate diet increases de novo fatty acid synthesis from glycerol and glycerokinase content in the liver of growing rats. Nutr Res 33, 494-502.
    
25. Foufelle F and Ferré P (2002) New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 366, 377-391.
    
26. Dentin R, Girard J and Postic C (2005) Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87, 81-86.
    
27. Iizuka K and Horikawa Y (2008) ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J 55, 617-624.
    
28. Kershaw EE, Hamm JK, Verhagen LA, Peroni O, Katic M and Flier JS (2006) Adipose triglyceride lipase: function, regulation by insulin, and comparison with adiponutrin. Diabetes 55, 148-157.
    
29. Zhai W, Xu C and Ling Y et al (2010) Increased lipolysis in adipose tissues is associated with elevation of systemic free fatty acids and insulin resistance in perilipin null mice. Horm Metab Res 42, 247-253.
    
30. Lumeng CN, Deyoung SM, Bodzin JL and Saltiel AR (2007) Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56, 16-23.
    
31. Petersen KF, Befroy D and Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140-1142.
    
32. Gual P, Le Marchand-Brustel Y and Tanti JF (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87, 99-109.
    
33. Schmitz-Peiffer C and Whitehead JP (2003) IRS-1 regulation in health and disease. IUBMB Life 55, 367-374.
    
34. Guilherme A, Virbasius JV, Puri V and Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9, 367-377.
    
35. Allameh A, Niayesh-Mehr R, Aliarab A, Sebastiani G and Pantopoulos K (2023) Oxidative stress in liver pathophysiology and disease. Antioxidants (Basel) 12, 1653.
    
36. Guo X, Yin X, Liu Z and Wang J (2022) Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci 23, 15489.
    
37. Mackay IR (2002) Hepatoimmunology: a perspective. Immunol Cell Biol 80, 36-44.
    
38. Freitas-Lopes MA, Mafra K, David BA, Carvalho-Gontijo R and Menezes GB (2017) Differential location and distribution of hepatic immune cells. Cells 6, 48.
    
39. Thomson AW and Knolle PA (2010) Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 10, 753-766.
    
40. Protzer U, Maini MK and Knolle PA (2012) Living in the liver: hepatic infections. Nat Rev Immunol 12, 201-213.
    
41. Crispe IN (2014) Immune tolerance in liver disease. Hepatology 60, 2109-2117.
    
42. Robinson MW, Harmon C and O'Farrelly C (2016) Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol 13, 267-276.
    
43. Pellicoro A, Ramachandran P, Iredale JP and Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14, 181-194.
    
44. Kubes P and Jenne C (2018) Immune responses in the liver. Annu Rev Immunol 36, 247-277.
    
45. Parthasarathy G, Revelo X and Malhi H (2020) Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 4, 478-492.
    
46. Kazankov K, Jorgensen SMD and Thomsen KL et al (2019) The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 16, 145-159.
    
47. Tang J, Yan Z, Feng Q, Yu L and Wang H (2021) The roles of neutrophils in the pathogenesis of liver diseases. Front Immunol 12, 625472.
    
48. Almeda-Valdes P, Aguilar Olivos NE, Barranco-Fragoso B, Uribe M and Mendez-Sanchez N (2015) The role of dendritic cells in fibrosis progression in nonalcoholic fatty liver disease. Biomed Res Int 2015, 768071.
    
49. Martinez-Chantar ML, Delgado TC and Beraza N (2021) Revisiting the role of natural killer cells in non-alcoholic fatty liver disease. Front Immunol 12, 640869.
    
50. Barrow F, Khan S, Wang H and Revelo XS (2021) The emerging role of B cells in the pathogenesis of NAFLD. Hepatology 74, 2277-2286.
    
51. Mao T, Yang R, Luo Y and He K (2022) Crucial role of T cells in NAFLD-related disease: a review and prospect. Front Endocrinol (Lausanne) 13, 1051076.
    
52. Kubes P and Mehal WZ (2012) Sterile inflammation in the liver. Gastroenterology 143, 1158-1172.
    
53. Nakamura K, Kageyama S and Kupiec-Weglinski JW (2019) The evolving role of neutrophils in liver transplant ischemia-reperfusion injury. Curr Transplant Rep 6, 78-89.
    
54. Fodor M, Salcher S and Gottschling H et al (2022) The liver-resident immune cell repertoire - a boon or a bane during machine perfusion?. Front Immunol 13, 982018.
    
55. Oliveira THC, Marques PE, Proost P and Teixeira MMM (2018) Neutrophils: a cornerstone of liver ischemia and reperfusion injury. Lab Invest 98, 51-62.
    
56. Cho Y and Szabo G (2021) Two faces of neutrophils in liver disease development and progression. Hepatology 74, 503-512.
    
57. Talukdar S, Oh DY and Bandyopadhyay G et al (2012) Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med 18, 1407-1412.
    
58. Chen J, Liang B and Bian D et al (2019) Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism. Biochem Biophys Res Commun 518, 691-697.
    
59. Zang S, Wang L and Ma X et al (2015) Neutrophils play a crucial role in the early stage of nonalcoholic steatohepatitis via neutrophil elastase in mice. Cell Biochem Biophys 73, 479-487.
    
60. Ibusuki R, Uto H and Arima S et al (2013) Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet. Liver Int 33, 1549-1556.
    
61. Yoshioka S, Mukae H and Ishii H et al (2007) Alpha-defensin enhances expression of HSP47 and collagen-1 in human lung fibroblasts. Life Sci 80, 1839-1845.
    
62. Pulli B, Ali M and Iwamoto Y et al (2015) Myeloperoxidase-hepatocyte-stellate cell cross talk promotes hepatocyte injury and fibrosis in experimental nonalcoholic steatohepatitis. Antioxid Redox Signal 23, 1255-1269.
    
63. Ye D, Yang K and Zang S et al (2016) Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. J Hepatol 65, 988-997.
    
64. Xu Y, Zhu Y and Jadhav K et al (2019) Lipocalin-2 protects against diet-induced nonalcoholic fatty liver disease by targeting hepatocytes. Hepatol Commun 3, 763-775.
    
65. Zhou Z, Xu MJ and Cai Y et al (2018) Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis. Cell Mol Gastroenterol Hepatol 5, 399-413.
    
66. Zhang H, van der Windt DJ, Ren J, Tsung A and Huang H (2019) The role of neutrophil extracellular traps in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. J Immunol 202(1_Supplement), 135.2.
    
67. Wang H, Zhang H and Wang Y et al (2021) Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. J Hepatol 75, 1271-1283.
    
68. van der Windt DJ, Sud V and Zhang H et al (2018) Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatology 68, 1347-1360.
    
69. Wu J, Zhang C and He T et al (2023) Polyunsaturated fatty acids drive neutrophil extracellular trap formation in nonalcoholic steatohepatitis. Eur J Pharmacol 945, 175618.
    
70. Fa P, Ke BG, Dupre A, Tsung A and Zhang H (2023) The implication of neutrophil extracellular traps in nonalcoholic fatty liver disease. Front Immunol 14, 1292679.
    
71. Zhao X, Yang L and Chang N et al (2020) Neutrophils undergo switch of apoptosis to NETosis during murine fatty liver injury via S1P receptor 2 signaling. Cell Death Dis 11, 379.
    
72. Du J, Zhang J and Chen X et al (2022) Neutrophil extracellular traps induced by pro-inflammatory cytokines enhance procoagulant activity in NASH patients. Clin Res Hepatol Gastroenterol 46, 101697.
    
73. Arelaki S, Koletsa T and Sinakos E et al (2022) Neutrophil extracellular traps enriched with IL-1beta and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis. Virchows Arch 481, 455-465.
    
74. He Y, Hwang S and Cai Y et al (2019) MicroRNA-223 ameliorates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes. Hepatology 70, 1150-1167.
    
75. Ariyachet C, Chuaypen N and Kaewsapsak P et al (2022) MicroRNA-223 suppresses human hepatic stellate cell activation partly via regulating the actin cytoskeleton and alleviates fibrosis in organoid models of liver injury. Int J Mol Sci 23, 9380.
    
76. Harty MW, Muratore CS and Papa EF et al (2010) Neutrophil depletion blocks early collagen degradation in repairing cholestatic rat livers. Am J Pathol 176, 1271-1281.
    
77. D'Amico F, Consolo M and Amoroso A et al (2010) Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection. Acta Histochem 112, 474-481.
    
78. Xu X, Poulsen KL and Wu L et al (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 7, 287.
    
79. Romero-Gomez M, Zelber-Sagi S and Trenell M (2017) Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 67, 829-846.
    
80. Phillips BE, Lantier L and Engman C et al (2022) Improvement in insulin sensitivity and prevention of high fat diet-induced liver pathology using a CXCR2 antagonist. Cardiovasc Diabetol 21, 130.
    
81. Leslie J, Mackey JBG and Jamieson T et al (2022) CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 71, 2093-2106.
    
82. Uchida Y, Freitas MC, Zhao D, Busuttil RW and Kupiec-Weglinski JW (2010) The protective function of neutrophil elastase inhibitor in liver ischemia/reperfusion injury. Transplantation 89, 1050-1056.
    
83. Koop AC, Thiele ND and Steins D et al (2020) Therapeutic targeting of myeloperoxidase attenuates nash in mice. Hepatol Commun 4, 1441-1458.
    
84. Wiering L and Tacke F (2023) Treating inflammation to combat non-alcoholic fatty liver disease. J Endocrinol 256, e220194.